
Subclinical left ventricular dysfunction (LVD) is a prelude to symptomatic heart failure (HF). We hypothesized that screening‐guided treatment with spironolactone would prevent incident HF in at‐risk patients. We randomized asymptomatic, community‐dwelling subjects aged ≥65 years old, with at least one non‐ischaemic HF risk factor (hypertension, type 2 diabetes mellitus or obesity) to echocardiography‐guided therapy or usual care. Spironolactone therapy was triggered by the detection of subclinical LVD (GLS ≤16% or diastolic abnormalities (at least one of E/e’>15, E/e’ >10 with left atrial enlargement [LAE] or impaired relaxation [E/A <0.8, IR], LAE with IR), or borderline GLS (17%) with IR or borderline GLS with LAE...
Like
Save
Share